Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ADXS-504 |
Trade Name | |
Synonyms | ADXS504|ADXS 504 |
Drug Descriptions |
ADXS-504 is an attenuated Listeria monocytogenes-based therapy containing a truncated fragment of listeriolysin O (tLLO) linked to 24 tumor-associated antigens, which potentially modulates the tumor microenvironment and reduces metastasis (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS5115). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C177282 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ADXS-504 | ADXS-504 | 0 | 1 |